Opportunities and challenges for the clinical application of multi-parameter flow cytometry in the era of chimeric antigen receptor-modified T cell immunotherapy
10.3760/cma.j.cn114452-20220307-00129
- VernacularTitle:嵌合抗原受体-T细胞治疗时代多参数流式细胞术临床应用的机遇与挑战
- Author:
Gusheng TANG
1
Author Information
1. 海军军医大学第一附属医院血液病科，上海200433
- Keywords:
Receptor;
Chimeric antigen;
T cells;
Multi-parameter flow cytometry;
Tumor immunity
- From:
Chinese Journal of Laboratory Medicine
2022;45(8):771-776
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric Antigen Receptor-modified(CAR)-T cells have become a new star living cell "drug" in the field of tumor immunotherapy, and five drugs have been available to the public since 2017. The favourable, rapid and efficient interaction of CAR-T therapy from bench to bedside has solved many new scientific problems, which remarkably expands the application field of multi-parameter flow cytometry (MFC). MFC participates the whole process of CAR-T preparation, functional evaluation, quality control, in vivo continuation evaluation, clinical efficacy and toxicity monitoring. New clinical problems caused by high-precision targeted therapy of CAR-T cells pose new challenges in using MFC for accurate tumor immunophenotyping, minimal residual disease monitoring, as well as the demands of comprehensively evaluation of the systematic immune function in different disease stages. In the era of targeted therapy, timely communication between laboratories and clinics is particularly important for obtaining accurate MFC results, which assists clinical individualized diagnosis and treatment.
